EGFR and cancer: Cetuximab, which was used to increase the cellular uptake of liposomes, is an anti-EGFR chimeric-murine monoclonal antibody, a biological drug that competitively binds to the EGFR on EGFR-positive cancer cells (e.g., DU145).